Cargando…
A Screening Study for the Development of Simvastatin-Doxorubicin Liposomes, a Co-Formulation with Future Perspectives in Colon Cancer Therapy
An increasing number of studies published so far have evidenced the benefits of Simvastatin (SIM) and Doxorubicin (DOX) co-treatment in colorectal cancer. In view of this, the current study aimed to investigate the pharmaceutical development of liposomes co-encapsulating SIM and DOX, by implementing...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537800/ https://www.ncbi.nlm.nih.gov/pubmed/34683821 http://dx.doi.org/10.3390/pharmaceutics13101526 |
_version_ | 1784588348680044544 |
---|---|
author | Barbălată, Cristina Ioana Porfire, Alina Silvia Sesarman, Alina Rauca, Valentin-Florian Banciu, Manuela Muntean, Dana Știufiuc, Rareș Moldovan, Alin Moldovan, Cristian Tomuță, Ioan |
author_facet | Barbălată, Cristina Ioana Porfire, Alina Silvia Sesarman, Alina Rauca, Valentin-Florian Banciu, Manuela Muntean, Dana Știufiuc, Rareș Moldovan, Alin Moldovan, Cristian Tomuță, Ioan |
author_sort | Barbălată, Cristina Ioana |
collection | PubMed |
description | An increasing number of studies published so far have evidenced the benefits of Simvastatin (SIM) and Doxorubicin (DOX) co-treatment in colorectal cancer. In view of this, the current study aimed to investigate the pharmaceutical development of liposomes co-encapsulating SIM and DOX, by implementing the Quality by Design (QbD) concept, as a means to enhance the antiproliferative effect of the co-formulation on C26 murine colon cancer cells co-cultured with macrophages. It is known that the quality profile of liposomes is dependent on the critical quality attributes (CQAs) of liposomes (drug entrapped concentration, encapsulation efficiency, size, zeta potential, and drug release profile), which are, in turn, directly influenced by various formulation factors and processing parameters. By using the design of experiments, it was possible to outline the increased variability of CQAs in relation to formulation factors and identify by means of statistical analysis the material attributes that are critical (phospholipids, DOX and SIM concentration) for the quality of the co-formulation. The in vitro studies performed on a murine colon cancer cell line highlighted the importance of delivering the optimal drug ratio at the target site, since the balance antiproliferative vs. pro-proliferative effects can easily be shifted when the molar ratio between DOX and SIM changes. |
format | Online Article Text |
id | pubmed-8537800 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85378002021-10-24 A Screening Study for the Development of Simvastatin-Doxorubicin Liposomes, a Co-Formulation with Future Perspectives in Colon Cancer Therapy Barbălată, Cristina Ioana Porfire, Alina Silvia Sesarman, Alina Rauca, Valentin-Florian Banciu, Manuela Muntean, Dana Știufiuc, Rareș Moldovan, Alin Moldovan, Cristian Tomuță, Ioan Pharmaceutics Article An increasing number of studies published so far have evidenced the benefits of Simvastatin (SIM) and Doxorubicin (DOX) co-treatment in colorectal cancer. In view of this, the current study aimed to investigate the pharmaceutical development of liposomes co-encapsulating SIM and DOX, by implementing the Quality by Design (QbD) concept, as a means to enhance the antiproliferative effect of the co-formulation on C26 murine colon cancer cells co-cultured with macrophages. It is known that the quality profile of liposomes is dependent on the critical quality attributes (CQAs) of liposomes (drug entrapped concentration, encapsulation efficiency, size, zeta potential, and drug release profile), which are, in turn, directly influenced by various formulation factors and processing parameters. By using the design of experiments, it was possible to outline the increased variability of CQAs in relation to formulation factors and identify by means of statistical analysis the material attributes that are critical (phospholipids, DOX and SIM concentration) for the quality of the co-formulation. The in vitro studies performed on a murine colon cancer cell line highlighted the importance of delivering the optimal drug ratio at the target site, since the balance antiproliferative vs. pro-proliferative effects can easily be shifted when the molar ratio between DOX and SIM changes. MDPI 2021-09-22 /pmc/articles/PMC8537800/ /pubmed/34683821 http://dx.doi.org/10.3390/pharmaceutics13101526 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Barbălată, Cristina Ioana Porfire, Alina Silvia Sesarman, Alina Rauca, Valentin-Florian Banciu, Manuela Muntean, Dana Știufiuc, Rareș Moldovan, Alin Moldovan, Cristian Tomuță, Ioan A Screening Study for the Development of Simvastatin-Doxorubicin Liposomes, a Co-Formulation with Future Perspectives in Colon Cancer Therapy |
title | A Screening Study for the Development of Simvastatin-Doxorubicin Liposomes, a Co-Formulation with Future Perspectives in Colon Cancer Therapy |
title_full | A Screening Study for the Development of Simvastatin-Doxorubicin Liposomes, a Co-Formulation with Future Perspectives in Colon Cancer Therapy |
title_fullStr | A Screening Study for the Development of Simvastatin-Doxorubicin Liposomes, a Co-Formulation with Future Perspectives in Colon Cancer Therapy |
title_full_unstemmed | A Screening Study for the Development of Simvastatin-Doxorubicin Liposomes, a Co-Formulation with Future Perspectives in Colon Cancer Therapy |
title_short | A Screening Study for the Development of Simvastatin-Doxorubicin Liposomes, a Co-Formulation with Future Perspectives in Colon Cancer Therapy |
title_sort | screening study for the development of simvastatin-doxorubicin liposomes, a co-formulation with future perspectives in colon cancer therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537800/ https://www.ncbi.nlm.nih.gov/pubmed/34683821 http://dx.doi.org/10.3390/pharmaceutics13101526 |
work_keys_str_mv | AT barbalatacristinaioana ascreeningstudyforthedevelopmentofsimvastatindoxorubicinliposomesacoformulationwithfutureperspectivesincoloncancertherapy AT porfirealinasilvia ascreeningstudyforthedevelopmentofsimvastatindoxorubicinliposomesacoformulationwithfutureperspectivesincoloncancertherapy AT sesarmanalina ascreeningstudyforthedevelopmentofsimvastatindoxorubicinliposomesacoformulationwithfutureperspectivesincoloncancertherapy AT raucavalentinflorian ascreeningstudyforthedevelopmentofsimvastatindoxorubicinliposomesacoformulationwithfutureperspectivesincoloncancertherapy AT banciumanuela ascreeningstudyforthedevelopmentofsimvastatindoxorubicinliposomesacoformulationwithfutureperspectivesincoloncancertherapy AT munteandana ascreeningstudyforthedevelopmentofsimvastatindoxorubicinliposomesacoformulationwithfutureperspectivesincoloncancertherapy AT stiufiucrares ascreeningstudyforthedevelopmentofsimvastatindoxorubicinliposomesacoformulationwithfutureperspectivesincoloncancertherapy AT moldovanalin ascreeningstudyforthedevelopmentofsimvastatindoxorubicinliposomesacoformulationwithfutureperspectivesincoloncancertherapy AT moldovancristian ascreeningstudyforthedevelopmentofsimvastatindoxorubicinliposomesacoformulationwithfutureperspectivesincoloncancertherapy AT tomutaioan ascreeningstudyforthedevelopmentofsimvastatindoxorubicinliposomesacoformulationwithfutureperspectivesincoloncancertherapy AT barbalatacristinaioana screeningstudyforthedevelopmentofsimvastatindoxorubicinliposomesacoformulationwithfutureperspectivesincoloncancertherapy AT porfirealinasilvia screeningstudyforthedevelopmentofsimvastatindoxorubicinliposomesacoformulationwithfutureperspectivesincoloncancertherapy AT sesarmanalina screeningstudyforthedevelopmentofsimvastatindoxorubicinliposomesacoformulationwithfutureperspectivesincoloncancertherapy AT raucavalentinflorian screeningstudyforthedevelopmentofsimvastatindoxorubicinliposomesacoformulationwithfutureperspectivesincoloncancertherapy AT banciumanuela screeningstudyforthedevelopmentofsimvastatindoxorubicinliposomesacoformulationwithfutureperspectivesincoloncancertherapy AT munteandana screeningstudyforthedevelopmentofsimvastatindoxorubicinliposomesacoformulationwithfutureperspectivesincoloncancertherapy AT stiufiucrares screeningstudyforthedevelopmentofsimvastatindoxorubicinliposomesacoformulationwithfutureperspectivesincoloncancertherapy AT moldovanalin screeningstudyforthedevelopmentofsimvastatindoxorubicinliposomesacoformulationwithfutureperspectivesincoloncancertherapy AT moldovancristian screeningstudyforthedevelopmentofsimvastatindoxorubicinliposomesacoformulationwithfutureperspectivesincoloncancertherapy AT tomutaioan screeningstudyforthedevelopmentofsimvastatindoxorubicinliposomesacoformulationwithfutureperspectivesincoloncancertherapy |